Inactive Instrument

Sanofi SA Stock Nyse

Equities

US80105N1054

Pharmaceuticals

Real-time Estimate Cboe BZX 09:27:05 2024-07-09 am EDT 5-day change 1st Jan Change
49.69 USD +16.45% Intraday chart for Sanofi SA -1.47% -1.47%
Sales 2024 * 46.33B 50.12B Sales 2025 * 49.75B 53.83B Capitalization 115B 125B
Net income 2024 * 7.04B 7.61B Net income 2025 * 8.57B 9.27B EV / Sales 2024 * 2.64 x
Net Debt 2024 * 6.95B 7.52B Net Debt 2025 * 2.51B 2.72B EV / Sales 2025 * 2.36 x
P/E ratio 2024 *
16.6 x
P/E ratio 2025 *
13.5 x
Employees -
Yield 2024 *
4.2%
Yield 2025 *
4.42%
Free-Float 87.13%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 40 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 62 20-04-27
Director/Board Member 64 20-05-21
More insiders
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company